Table 2. Association of clinical variables with sunitinib-induced adverse events.

Adverse event	Gender			ECOG performance status			Age			RCC histology
	P-value	OR	95%CI	P-value	OR	95%CI	P-value	OR	95%CI	P-value	OR	95%CI
Increased AST/ALT	1.83E-01	1.975	0.725–5.380	9.82E-01	1.009	0.458–2.223	6.77E-01	0.990	0.946–1.037	3.62E-01	0.576	0.176–1.886
Diarrhea	2.71E-01	0.49	0.137–1.748	2.16E-01	0.494	0.162–1.510	7.25E-01	0.992	0.949–1.037	6.36E-01	1.445	0.315–6.635
Fever	2.73E-01	0.426	0.092–1.963	8.33E-01	1.096	0.468–2.568	1.55E-01	0.965	0.918–1.014	9.38E-01	1.063	0.226–5.010
Hand-foot syndrome	6.55E-01	1.157	0.610–2.192	4.87E-02	0.576	0.332–0.997	2.46E-01	0.984	0.957–1.011	9.01E-01	1.054	0.463–2.397
Hypertension	9.86E-01	1.007	0.466–2.176	4.06E-01	1.241	0.745–2.068	2.73E-01	1.019	0.985–1.055	8.02E-01	0.882	0.331–2.355
Hypothyroidism	5.02E-01	1.241	0.661–2.330	7.71E-01	0.931	0.574–1.509	8.86E-01	0.998	0.972–1.025	4.05E-01	0.717	0.328–1.568
Leucopenia	1.46E-02	2.504	1.199–5.228	6.50E-01	1.136	0.656–1.965	6.47E-02	1.036	0.998–1.076	7.92E-02	0.440	0.176–1.100
Neutropenia	2.81E-01	1.466	0.732–2.935	1.62E-01	0.656	0.363–1.185	5.28E-01	1.010	0.979–1.042	1.73E-01	0.554	0.236–1.296
Proteinuria	5.61E-01	0.776	0.331–1.823	6.54E-01	1.137	0.649–1.992	4.22E-02	1.041	1.001–1.083	7.53E-01	1.199	0.387–3.712
Thrombocytopenia	9.27E-01	1.029	0.560–1.890	2.09E-01	0.745	0.470–1.180	7.77E-03	1.039	1.010–1.069	1.91E-01	0.595	0.273–1.296

Analysis was examined with patients who developed adverse reaction of increased AST/ALT (grade 3 and 4 versus others), diarrhea (grade2 to 4 versus others), fever (grade2 to 4 versus others), hand-foot syndrome (grade2 to 4 versus others), hypertension (grade 3 and 4 versus others), hypothyroidism (grade2 to 4 versus others), leucopenia (grade 3 and 4 versus others), neutropenia (grade 3 and 4 versus others), proteinuria (grade2 to 4 versus others) and thrombocytopenia (grade 3 and 4 versus others). Abbreviations: OR, odds ratio; CI, confidence interval.